Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takamitsu Inoue

Showing results (161-170 of 185) with videos related to

Pageof 19
Sort By:
Clinical Genitourinary Cancer|November 5, 2018
Radical Prostatectomy With and Without Neoadjuvant Chemohormonal Pretreatment for High-Risk Localized Prostate Cancer: A Comparative Propensity Score Matched AnalysisShintaro Narita, Taketoshi Nara, Sohei Kanda, et al.
International Journal of Clinical Oncology|October 17, 2020
Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective studyKoichi Kido, Shingo Hatakeyama, Kazuyuki Numakura, et al.
International Journal of Cancer|May 8, 2014
Effects of functional genetic polymorphisms in the CYP19A1 gene on prostate cancer risk and survivalSohei Kanda, Norihiko Tsuchiya, Shintaro Narita, et al.
International Journal of Clinical Oncology|June 29, 2016
Current status of systemic chemotherapy for octogenarians with advanced urothelial cancer in Japan: a Japanese multi-institutional study (CURE study)Yoshiyuki Matsui, Osamu Ogawa, Ryutaro Ishitsuka, et al.
Hinyokika Kiyo. Acta Urologica Japonica|November 8, 2019
[METASTATIC Mucinous Tubular and Spindle Cell Carcinoma Treated with Nivolumab Successfully : A Case Report]Yoshiko Takahashi, Kazuyuki Numakura, Yu Aoyama, et al.
Cancer Reports (Hoboken, N.J.)|June 17, 2026
Assessment of Multiple Prognostic Scores in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line, Immune-Based CombinationsHiromichi Sakurai, Masanobu Shiga, Shuya Kandori, et al.
Hinyokika Kiyo. Acta Urologica Japonica|October 17, 2006
[A case of myxoid liposarcoma in the right inguinal region: a case report]Kenji Yoshida, Eijiro Nakamurai, Takashi Kawahara, et al.
Cancer Research Communications|September 5, 2025
Prognostic impact of immune-related adverse events on combination immune checkpoint/tyrosine kinase inhibition for metastatic renal cancerBunpei Isoda, Masanobu Shiga, Shuya Kandori, et al.
International Journal of Clinical Oncology|June 21, 2019
Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analysesChikara Ohyama, Takahiro Kojima, Tsunenori Kondo, et al.
International Journal of Clinical Oncology|May 13, 2020
Efficacy and safety of nivolumab for renal cell carcinoma in patients over 75 years old from multiple Japanese institutesKazuyuki Numakura, Mizuki Kobayashi, Shingo Hatakeyama, et al.
Pageof 19

Showing results (161-170 of 185) with videos related to

Sort By:
Pageof 19
Clinical Genitourinary Cancer|November 5, 2018
Radical Prostatectomy With and Without Neoadjuvant Chemohormonal Pretreatment for High-Risk Localized Prostate Cancer: A Comparative Propensity Score Matched AnalysisShintaro Narita, Taketoshi Nara, Sohei Kanda, et al.
International Journal of Clinical Oncology|October 17, 2020
Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective studyKoichi Kido, Shingo Hatakeyama, Kazuyuki Numakura, et al.
International Journal of Cancer|May 8, 2014
Effects of functional genetic polymorphisms in the CYP19A1 gene on prostate cancer risk and survivalSohei Kanda, Norihiko Tsuchiya, Shintaro Narita, et al.
International Journal of Clinical Oncology|June 29, 2016
Current status of systemic chemotherapy for octogenarians with advanced urothelial cancer in Japan: a Japanese multi-institutional study (CURE study)Yoshiyuki Matsui, Osamu Ogawa, Ryutaro Ishitsuka, et al.
Hinyokika Kiyo. Acta Urologica Japonica|November 8, 2019
[METASTATIC Mucinous Tubular and Spindle Cell Carcinoma Treated with Nivolumab Successfully : A Case Report]Yoshiko Takahashi, Kazuyuki Numakura, Yu Aoyama, et al.
Cancer Reports (Hoboken, N.J.)|June 17, 2026
Assessment of Multiple Prognostic Scores in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line, Immune-Based CombinationsHiromichi Sakurai, Masanobu Shiga, Shuya Kandori, et al.
Hinyokika Kiyo. Acta Urologica Japonica|October 17, 2006
[A case of myxoid liposarcoma in the right inguinal region: a case report]Kenji Yoshida, Eijiro Nakamurai, Takashi Kawahara, et al.
Cancer Research Communications|September 5, 2025
Prognostic impact of immune-related adverse events on combination immune checkpoint/tyrosine kinase inhibition for metastatic renal cancerBunpei Isoda, Masanobu Shiga, Shuya Kandori, et al.
International Journal of Clinical Oncology|June 21, 2019
Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analysesChikara Ohyama, Takahiro Kojima, Tsunenori Kondo, et al.
International Journal of Clinical Oncology|May 13, 2020
Efficacy and safety of nivolumab for renal cell carcinoma in patients over 75 years old from multiple Japanese institutesKazuyuki Numakura, Mizuki Kobayashi, Shingo Hatakeyama, et al.
Pageof 19